Mosquirix is the name of this first vaccine against malaria which will be massively deployed in the coming days among children living in risk areas.
Indeed, the World Health Organization (WHO) recommended, Wednesday, October 6, the massive deployment of the first vaccine against malaria in children living in sub-Saharan Africa and in areas at risk, which could save tens of thousands lives.
"This is a historic moment. The long-awaited malaria vaccine for children is a breakthrough in science, child health and the fight against malaria. The use of this vaccine, in addition to existing tools to prevent malaria, could save tens of thousands of young lives every year,"said WHO Director-General Dr Tedros Adhanom Ghebreyesus.
Manufactured by British pharmaceutical giant Glaxo Smith Kline (GSK), Mosquirix, also known as RTS, S, is the first vaccine, and the only one so far, to have shown efficacy in significantly reducing the number of cases of malaria, including including severe, life-threatening malaria in children.
In May 2018, the national regulatory authorities of Ghana, Kenya and Malawi authorized its use in the pilot areas. Two years after the start of this first full-scale test in the world, 2.3 million doses of vaccine could be administered.
According to the WHO, phase 3 clinical trials have shown that the vaccine, when given in four doses, prevents four in ten cases of malaria, and three in ten cases of severe, life-threatening malaria.
A very old disease, reported since Antiquity, malaria manifests itself by fever, headaches and muscle pains, then by cycles in which chills, fever and sweating alternate. A child dies every two minutes from malaria around the world, according to the WHO.
This is a giant and historic step in the fight against malaria. It thus crowns an effort of more than a century.